Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) has announced its participation in the virtual Cantor Global Healthcare Conference from September 27-30, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) has announced its participation in the virtual Cantor Global Healthcare Conference from September 27-30, 2021. During this event, Dr. Alon Seri-Levy and CFO Gilad Mamlok will engage in a fireside chat discussion on September 30, starting at 10:40 a.m. ET. The discussion will be available on demand, and a replay can be accessed for 30 days. Sol-Gel focuses on developing topical dermatology treatments, leveraging proprietary technologies for products like TWYNEO and EPSOLAY. For more information, visit their official website.
Details
News Market Reaction – SLGL
The recorded move for SLGL in the trading session of this news was -6.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27th – 30th, 2021.
| Cantor Global Healthcare Conference Presentation Information: | |
| Format | Fireside chat discussion and 1-on-1 meetings |
| Speaker: | Dr. Alon Seri-Levy, Chief Executive Officer and Mr. Gilad Mamlok, Chief Financial Officer |
| Date: | Thursday, September 30th |
| Time: | Discussion available on demand beginning Thursday, September 30th 10:40 a.m. ET (TRACK 3) |
| To Listen | To listen to the discussion, click here. A replay will be archived for 30 days at this link (or go to www.sol-gel.com to access within the Investors/Events and Presentations section). |
About Sol-Gel Technologies
Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed for U.S. commercialization with Galderma.
The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream,
For additional information, please visit www.sol-gel.com.
Contact:
Irina Koffler
Investor relations, LifeSci Advisors
ikoffler@lifesciadvisors.com
+1-917-734-7387
Sol-Gel Technologies
Gilad Mamlok
Chief Financial Officer
gilad.mamlok@sol-gel.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.